Intec Says Phase 3 Trial Did Not Achieve Statistical Superiority To Sinem

Intec Pharma Ltd. (NTEC) announces Monday top-line data from the Company's pivotal Phase 3 ACCORDANCE trial evaluating the safety and efficacy of the Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) compared with immediate release CD/LD (IR-CD/LD; Sinemet) as a treatment for the symptoms of advanced Parkinson's disease (PD).

from RTT - Biotech https://ift.tt/2M2prRf
via IFTTT